Small-cap biotechs scorched

A little bit more air comes out of the previously scorching small-cap biotech names today. Among them: CytRx (CYTR -4.8%), Dyax (DYAX -5.2%), Galena (GALE -9.6%), Novavax (NVAX -9%), Arena (ARNA -6.3%), Synta (SNTA -10.8%), Zogenix (ZGNX -3.5%), Tonix (TNXP -8.4%).


From other sites
Comments (23)
  • WhitneyB
    , contributor
    Comments (903) | Send Message
    Ouch, ouch, ouch - out until these charts turn
    27 Jan 2014, 10:55 AM Reply Like
  • Noobluechips
    , contributor
    Comments (18) | Send Message
    Ugh this hurts.
    27 Jan 2014, 10:56 AM Reply Like
  • joelkatz
    , contributor
    Comments (570) | Send Message
    I see an opportunity here
    27 Jan 2014, 11:00 AM Reply Like
  • chadm
    , contributor
    Comments (35) | Send Message
    Yep... discounts. The best buys IMO... NVAX, CYTR, and TNXP. Safest bets among this group... with very nice upside...heavy institutional and insider ownership on all 3.
    27 Jan 2014, 11:02 AM Reply Like
  • user418
    , contributor
    Comments (264) | Send Message
    PRAN is the best of the lot !!!!!!!!!!!
    27 Jan 2014, 11:09 AM Reply Like
  • enigma_mttrrnd
    , contributor
    Comments (31) | Send Message
    Yay... Not going to liquidate but not going to pursue any more shares until the dust settles. Focused on $CYTR, $GALE, & $TNXP as I believe them to be the more attractive companies for 2014
    27 Jan 2014, 11:17 AM Reply Like
  • rooksmith
    , contributor
    Comments (101) | Send Message
    The selling this morning seems to have slowed to a crawl. Its just a healthy selloff if a volatile sub sector. These stocks mirror the $IBB x3 , but sometimes explode upward. Good time to buy if the markets calm down.
    27 Jan 2014, 11:31 AM Reply Like
  • jonomatic_2000
    , contributor
    Comments (39) | Send Message
    add shares if you can and hold the line.
    27 Jan 2014, 11:41 AM Reply Like
  • 21388691
    , contributor
    Comments (6) | Send Message
    Do you think Gale will hit $7 anytime soon? There seems to be so much potential with this company's upcoming drugs but the downward fall in the last week isn't very comforting....
    27 Jan 2014, 11:47 AM Reply Like
  • rudynostalgia
    , contributor
    Comment (1) | Send Message
    THLD is in bargain range as well as SPPI.
    27 Jan 2014, 11:47 AM Reply Like
  • jeflieb
    , contributor
    Comments (4) | Send Message
    gale vs gnbt gnbt required a large n gale did not stay buy gale
    27 Jan 2014, 12:11 PM Reply Like
  • Retail Investor
    , contributor
    Comments (904) | Send Message
    What I have been warning for last several weeks. We have a huge bubble in development stage biotech.
    27 Jan 2014, 12:55 PM Reply Like
  • cain@19445
    , contributor
    Comments (9) | Send Message
    chadm, do you mean Ino ??
    27 Jan 2014, 01:26 PM Reply Like
  • easydom
    , contributor
    Comments (98) | Send Message
    IMO = in my opinion
    27 Jan 2014, 01:33 PM Reply Like
  • Francisco Javier Garcia
    , contributor
    Comments (25) | Send Message
    I own CYTR and expect holding for long time.
    27 Jan 2014, 01:48 PM Reply Like
  • Rope a Dope
    , contributor
    Comments (708) | Send Message
    This entire sector has been extremely volatile since ICPT went stratospheric a few weeks ago.
    27 Jan 2014, 02:06 PM Reply Like
  • Carlitos0311
    , contributor
    Comment (1) | Send Message
    GALE has been particularly hit hard in the last trading sessions. However, this company has incredible potential and has already proved it. I don't know why people freak out. You didn't expect to be green all the time did you? GALE may go lower, perhaps into the mid $4s but it won't matter when Abstral sales and NeuVax drive it to $12 +, and based on its track record, it will. Finally, for those of us who bought GALE more than a year ago, we have, at least, doubled our investment. Look at the science behind it and not at the crisis in the emerging markets. GALE is a BUY. Whoever disagrees, show me the numbers to prove otherwise.
    27 Jan 2014, 05:29 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (884) | Send Message
    completely agree. It is disconcerting to see my biotech fall so hard, but that is the nature of the game. The sell off is basically on no news. For GALE in particular, I think some manipulation is going on with the big boys so they can scoop it cheaper prior to GALES quarter announcement where abstral sales will bring this company up to a 1 billion market cap.
    27 Jan 2014, 06:06 PM Reply Like
  • joenobody02
    , contributor
    Comments (17) | Send Message
    I reduced my GALE position substantially. Holding the remaining shares just in case. Long term, GNBT has a better mouse trap.
    27 Jan 2014, 06:02 PM Reply Like
  • joenobody02
    , contributor
    Comments (17) | Send Message
    ARNA is a monster in the making and is safer than most since its drug is already on the market.
    27 Jan 2014, 06:03 PM Reply Like
  • Hdrdr1999
    , contributor
    Comments (9) | Send Message
    RXII dodged the general massacre...
    27 Jan 2014, 08:02 PM Reply Like
  • japalm
    , contributor
    Comments (5) | Send Message
    I am long GALE and expect their Abstral sales to be stronger than expected and really drive up the company's value (and stock price) when they are announced sometime in March.
    28 Jan 2014, 01:03 AM Reply Like
  • Long_Bio
    , contributor
    Comments (6) | Send Message
    Three GALE board members sold a total of 850,000 shares in mid-January, leaving two of the three holding 5,000 or fewer shares. I was long GALE but sold on this news and negative comments from Cramer that Dr. Ahn, CEO, failed to dispute when he was a guest on Mad Money. I got burned on Zalicus and I'm not going to risk losing thousands again with GALE. And have you seen the shorts lately: 23% of outstanding shares are short, and it's increasing. I'm not short, and obviously not long. I'm just sharing news that should be part of each shareholder's due diligence.
    28 Jan 2014, 11:19 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs